MUC1 is aberrantly expressed in greater than 90% of all breast carcinomas, yet its function as a tumor antigen is not fully understood. Recently, studies have shown that MUC1 interacts with b-catenin, erbB receptors, src, GSK-3b and protein kinase Cd, possibly in a complex that promotes the disassembly of adherens junctions and the invasion of cells. Here we show that the deletion of Muc1 expression from MMTV-Wnt-1 transgenic mice results in a significant increase in the time to mammary gland tumor onset. Analysis of MMTV-Wnt-1 tumors on a wild-type Muc1 background shows a tumor-specific complex formation between Muc1 and b-catenin that can be observed in both the membrane and the cytoplasm of transformed epithelium. Analysis of primary human adenocarcinomas revealed that this MUC1/b-catenin interaction occurs in both primary and metastatic tumors, but is dramatically increased in metastatic lesions. Addition of MUC1-cytoplasmic domain peptides to the invasive MDA-MB-468 and MDA-MB-231 cell lines increases their invasive capability, and these peptides colocalize with both b-catenin and the focal adhesion protein vinculin, primarily at sites of membrane invasion into a collagen matrix. These data indicate a potential mechanism for MUC1 promotion of invasive tumorigenesis in the breast through the modulation of b-catenin localization and subsequent cytoskeletal dynamics.
Introduction
Metastatic invasion in breast cancer is a critical event leading to patient mortality, and the identification of molecular events specific to metastasis is essential to the development of effective therapies. For more than 20 years, MUC1 (PEM, episialin, EMA, CD227, DF3) has been identified as a human breast tumor antigen, overexpressed on greater than 90% of those samples analysed (Zotter et al., 1988) . This striking number indicates a meaningful correlation between MUC1 overexpression and breast cancer progression. Initial studies were focused on the heavily glycosylated extracellular domain of MUC1, suggesting that its extended rod-like conformation (extending >200 nm above the glycocalyx) on the apical surface of polarized epithelia resulted in productive and lubricated lumens . Alternatively, MUC1 is expressed throughout the plasma membrane and cytoplasm of transformed cells , and it has been hypothesized that this promotes cellular dissociation through steric masking of adhesion receptors .
Recently, the highly conserved cytoplasmic domain of MUC1 has gained interest, as a number of protooncogenes were identified to interact with MUC1, such as EGFR, c-src and b-catenin (Yamamoto et al., 1997; Li et al., 2001a, b; Schroeder et al., 2001) . In vitro studies show that a defined sequence in the cytoplasmic tail of MUC1 (SXXXXXSSLS) interacts with b-catenin, and can compete with E-cadherin at adherens junctions for binding of b-catenin when expressed at high levels (Yamamoto et al., 1997) . The serine/threonine kinase GSK-3b can also bind the cytoplasmic domain of MUC1, and in fact, binding to this kinase competes away binding between MUC1 and b-catenin in breast cancer cell lines, presumably allowing for normal binding between b-catenin and E-cadherin (Li et al., 1998) . Finally, both src and the erbB receptor tyrosine kinases phosphorylate MUC1, as well as the serine/ threonine kinase Protein Kinase C delta (PKCd), and these phosphorylation events promote interactions between b-catenin and MUC1 (Li et al., 2001b; Schroeder et al., 2001; Ren et al., 2002) . MUC1 has been previously described to balance the adhesion properties of cells, primarily through modulation of integrin-mediated adhesion of melanoma cell lines . Furthermore, MUC1 overexpression can suppress the normal E-cadherin function of breast cancer cell lines (Wesseling et al., 1996; Kondo et al., 1998) . These studies point to a role for MUC1 in controlling cell adhesion and, alternatively, cell invasion into the microenvironment.
Our studies have focused on the interaction between b-catenin and MUC1 in the promotion and invasion of breast cancer. We have found that Muc1 is important in the development of mammary gland tumors in the MMTV-Wnt-1 transgenic mouse model and discovered a striking correlation between MUC1/b-catenin binding and metastatic progression in human disease. We have found that MUC1 is a critical component of this metastatic complex, as binding of the MUC1 cytoplasmic tail to b-catenin results in the redistribution of b-catenin to invading cell margins. Overall, these studies point to a mechanism for the observation of an MUC1/ b-catenin complex formation in the metastatic spread of breast cancer, which is the modulation of the cytoskeleton during invasion.
Results

Loss of Muc1 delays tumor onset in MMTV-Wnt-1 mice
To determine the effect of Muc1 expression on bcatenin-induced breast cancer, we crossed the MMTVWnt-1 transgenic line onto a Muc1 null background (Tsukamoto et al., 1988; Spicer et al., 1995) . Overexpression of Wnt-1 in the mammary glands of transgenic mice results in the formation of tumors because of an accumulation of intracellular b-catenin, which in turn promotes transformation (Michaelson and Leder, 2001 ). MMTV-Wnt-1 transgenics stochastically develop nonmetastasizing, unifocal mammary tumors with a mean latency of approximately 14 weeks of age (Li et al., 2000) . A total of 20 MMTV-Wnt-1/Muc1 À/À transgenics and 27 MMTV-Wnt-1 transgenics on a wildtype Muc1 background (MMTV-Wnt-1/Muc1 +/+ ) were palpated weekly, and tumors were determined to have formed when masses on the mammary gland reached between 0.5 and 1.0 cm in size. While MMTV-Wnt-1/ Muc1 +/+ mice developed mammary tumors at approximately the same time as previously published reports (50% tumor incidence at 16 weeks), MMTV-Wnt-1/ Muc1 À/À transgenics displayed a significantly increased onset time to tumor formation of approximately 30 weeks (Po0.03 using a Wilcoxon-Gehan-Breslow test) (Figure 1 ). b-Catenin protein expression and phosphorylation levels were found to be similar between both groups by Western blot analysis, and the overall number of tumors forming per mouse (1.1 tumor per mouse) and growth rate of individual tumors were similar between the groups (data not shown).
To verify an interaction between Muc1 and b-catenin in these tumors, normal mammary glands and tumors from MMTV-Wnt-1/Muc1 +/+ animals were homogenized and protein lysates were prepared. Analysis of the tumors from nulliparous wild-type MMTV-Wnt-1/ Muc1 +/+ transgenics demonstrated a strong interaction between Muc1 and b-catenin that was highly upregulated in the tumor versus the virgin gland (Figure 2 ). Muc1 expression was generally higher in the tumor versus the normal gland, with 64% of the animals analysed displaying this pattern of increased expression in the tumor. Interestingly, in the 36% of animals displaying equal levels of Muc1 and b-catenin expression, coimmunoprecipitation experiments also showed an increased interaction in the tumor versus the normal mammary gland (Figure 2a , first three lanes), indicating that the increase in interaction is not merely because of an increase in expression. Histological analysis of the two tumor genotypes revealed that both were P-type tumors, having a branching ductile pattern with basaloid masses at the terminal ends. Additionally, these masses are in dense connective tissue, a phenotype that is typical of the activated Wnt-1 pathway (Robert Cardiff, personal communication) .
To investigate the effect of MUC1 overexpression on MMTV-Wnt-1 driven mammary gland tumorigenesis, we have created MMTV-Wnt-1 Â MMTV-MUC1 fulllength transgenics (Schroeder et al., 2001) . We have identified no change in the time for tumor formation, in the number of tumors formed or in their rate of growth. In one bitransgenic animal, we did identify a single pulmonary metastasis, whereas we have never detected one in MMTV-Wnt-1 transgenics. Use of these bitransgenic tissues have allowed us to colocalize transgenic MUC1 and b-catenin in the tumor, and colocalization can be observed throughout the cytoplasm and plasma membrane (Figure 2b ).
MUC1 and b-catenin interactions are strongly induced in metastasis
Increased levels of MUC1 have been observed in the sera of breast cancer patients and are frequently highly expressed on tissue sections from invasive breast cancer biopsies (Burchell et al., 1984; McGuckin et al., 1995) . Furthermore, b-catenin has been found upregulated in breast cancer patients, and relocalization of b-catenin À/À animals was B47% slower than those animals with wild-type Muc1 expression (when 50% of the animals had formed tumors). Tumor formation was determined when a palpable mass reached 0.5-1.0 cm in diameter and remained upon subsequent palpation Alteration of tumor formation by MUCI JA Schroeder et al from the membrane to the cytoplasm and nuclear compartment is frequently associated with poor patient prognosis (Lin et al., 2000) . Interactions between MUC1 and b-catenin have been previously described in cultured cells (Yamamoto et al., 1997; Li et al., 1998 Li et al., , 2001a , and we have analysed 12 patients diagnosed with infiltrating ductal breast carcinoma to determine both the levels of MUC1 and b-catenin expression and extent of protein interaction. We have observed an increase in protein levels for both b-catenin ( Figure 3a ) and MUC1 ( Figure 3b ) in primary breast cancer and metastatic lymph nodes when compared to normal breast (Figure 3a, b) . Through coimmunoprecipitation experiments of tumor and normal breast lysates, we have found that MUC1 and b-catenin do interact in a tumor-specific fashion. While we were unable to detect interactions between MUC1 and b-catenin in normal breast samples, even in those samples expressing equivalent levels of both proteins (four of 12 normal breast specimens), we were able to detect interactions quite readily in both the primary tumor and lymph node metastasis ( Figure 3a and data not shown). Importantly, while b-catenin and MUC1 coimmunoprecipitated in seven of 11 primary breast tumors (64%), the proteins interacted in all seven lymph node metastases examined (100%) (Figure 3a and data not shown). Additionally, the levels of interaction between MUC1 and b-catenin appear to be much increased in the lymph node metastases compared to the primary tumors ( Figure 3a and data not shown). These observations indicate that the interaction between MUC1 and b-catenin may be specifically upregulated in metastatic cancer.
As localization of b-catenin can be correlated to overall patient outcome (Lin et al., 2000) , we investigated the localization of these interacting proteins in the normal breast, the primary tumor and the axillary lymph node metastasis. Nonquantitative (Figure 4c ), but not the normal breast (Figure 4a ). Importantly, note that the localization of these proteins appears to change with the state of transformation of the tissue. Namely, while MUC1 is highly apically localized and b-catenin is membranous (mostly basolateral) and cytoplasmic in the normal breast, colocalization of these proteins can be observed both in the membrane and cytoplasm of the tumor and metastasis (Figure 4, a-c) .
Peptides representing the GSK-3b/b-catenin-binding region of MUC1 promote invasion MUC1 and b-catenin coimmunoprecipitate primarily in metastatic lymph nodes, indicating that the interaction is upregulated specifically in invasive carcinoma. To investigate the effect of MUC1 expression on breast cancer invasion, we have incubated breast cancer cell lines with peptides designed to the MUC1 cytoplasmic domain and monitored the effect on invasion in a Transwell assay. The peptides were designed to mimic the region of MUC1 shown to interact with GSK-3b, c-src and b-catenin (Li et al., 1998) , and have been synthesized either phosphorylated or nonphosphorylated on the tyrosine residues ( Figure 5a ). MUC1 is frequently observed to be tyrosine phosphorylated in vitro (Zrihan-Licht et al., 1994) and in vivo (Schroeder et al., 2001) , and the highly conserved tyrosine residues are targets for both EGFR and c-src kinases (Li et al., 2001a, b; Schroeder et al., 2001) . We designed a 24-mer MUC1-specific peptide that encompasses the DRSPY sequence of MUC1 responsible for GSK-3b binding, continues through the YEKV-binding site for c-src and ends at the SAGNGGSSL b-catenin-binding site (M1 and M1pY). To determine the requirement of each binding domain for function, we also designed subdomain peptides containing either an 11-mer specific to the b-catenin-binding site (M2 and M2pY) or an 8-mer specific to the GSK-3b-binding site of MUC1 (M3 and M3pY, Figure 5b ). Additionally, a nonphosphorylated 17-mer peptide (MUC1-CT) whose N-terminus encompassed the SSLS motif contained within the bcatenin-binding site, and a non-b-catenin-binding phosphorylated peptide (M4pY) from elsewhere in the MUC1 cytoplasmic domain were used as controls. Utilizing a Transwell invasion assay (modified Boyden's chamber assay), we analysed the invasive capability of MDA-MB-468, MDA-MB-231 and ZR-75-1 breast cancer cell lines. MDA-MB-468 and ZR-75-1 cells express high levels of MUC1, while MDA-MB-231 cells express barely detectable levels ( (Walsh et al., 1999; Schroeder et al., 2001 ) and data not shown). Transwell inserts were modified by coating the bottom of the filter with a Type I Collagen gel matrix, allowing the cells to migrate into the gel, and then enumerating cells that had migrated fully into the collagen matrix. After the incubation period, the collagen gel was removed from the transwell, cells were stained with bisbenzamide, and the nuclei of the invading cells were enumerated. Upon Tyrosine phosphorylation of the peptides yielded no significant difference in the ability of the peptide to promote invasion (Figure 5c compare M1 to M1pY). This could indicate that either the phosphorylation is irrelevant to the invasive capacity of the peptide, or that the peptides are being phosphorylated or dephosphorylated in vivo. The use of two smaller peptides, representing either the individual GSK-3b or b-catenin sites resulted in invasive capabilities similar to PBS/ bioPORTER vehicle alone (Figure 5c, M2 and M3 ). Note that Figure 5c represents an invasion assay that was performed for only 2.5 h with a final peptide concentration of 100 mM, in an effort to lower the total cell numbers and make the enumeration of nuclei more precise. The increase in invasion that was observed varied with the time the assay was allowed to progress, in that a 2 h invasion assay resulted in only a five-fold increase in invasion (Figure 5c ), a 4-5 h invasion assay resulted in a 10-fold increase and a 24 h invasion assay showed both the peptide-treated and -untreated collagen gels completely saturated with invading cells (data not shown).
To verify internalization of the biotinylated peptide, immunofluorescence was performed on the collagen gel, using a streptavidin probe. Analysis of the internalized biotinylated peptide in MDA-MB-468 cells localized the M1pY peptide throughout the cell, with highly localized perinuclear and membrane staining (Figure 6a,c) . Analysis of nonspecific peptide localized it throughout the cell (M4pY), with a somewhat random distribution, although highly localized perinuclear staining was also observed (Figure 6b ).
MUC1 and b-catenin associate at the invading cell membrane
To determine colocalization between b-catenin and the peptide, collagen gels were immunofluorescently labeled with antibodies to endogenous b-catenin and biotinlabeled peptide. Colocalization occurred primarily at cell membranes, particularly where cells were making focal adhesions to the collagen matrix. Additionally, cell-cell borders of dividing cells and lamellipodia of invading cells displayed particularly strong colocalization (Figure 6a,c) . To verify the localization of the MUC1 and b-catenin interaction, cells were also stained with vinculin (which is a marker for sites of focal adhesion), and fascin (an actin-bundling protein frequently observed at invading membranes (Yamashiro et al., 1998) ). Fascin is known to promote the migration and invasion of cells and to associate with b-catenin during these processes (Tao et al., 1996; Yamashiro et al., 1998) . Colocalization between fascin/b-catenin and vinculin/MUC1 was found to occur primarily at Figure 5 MUC1 cytoplasmic domain peptides increase invasion of MDA-MB-468 cells. Cells were incubated with peptides, and analysed for their ability to migrate through an 8 mm Transwell filter insert and into a 1% Type I collagen matrix, using serum as a chemoattractant. After the incubation period, invading cells were stained with bisbenzamide and enumerated. (a) The cytoplasmic domain of MUC1 is shown with protein interaction sites bracketed for GSK3b, c-src/EGFR, PKCd and b-catenin. Specific peptide sequences are shown below, with phosphorylated tyrosine residues blocked, including the nonspecific MUC1 peptides used for negative controls (M4pY and MUC1-CT). (b) Phosphorylated M1pY peptide (4 mm) was analysed during a 4-h time period, with a 10-fold increase in invasion observed over either PBS/BioPORTER vehicle alone or nonspecific MUC1 phosphopeptide (n ¼ 5). (c) Peptides and phosphopeptides (100 mm) representing either GSK3b (M3)-or b-catenin (M2)-binding sites for MUC1 were compared to M1 and M1pY for invasive capability. Experiments were allowed to proceed for 2.5 h and performed in duplicate (similar results were achieved (n ¼ 3, in duplicate)). For all assays, cells were enumerated under Â 100 magnification and all cells in the collagen gel were counted. S.d. are shown sites of focal adhesion and membrane invasion into the collagen matrix (Figure 6d-f) . Verification of vinculinstaining membrane protrusions is shown in Figure 6e and f, with phalloidin counter staining of cytoplasmic actin shown as a control in Figure 6e .
Discussion
We have found that Muc1 expression promotes the b-catenin-induced onset of mammary gland carcinoma by crossing the MMTV-Wnt-1 transgenic model of tumorigenesis onto a Muc1-null background. We have additionally determined that the specific interactions between MUC1 and b-catenin are highly increased in the lymph node metastases of human invasive ductal adenocarcinomas. Finally, through treatment of breast cancer cell lines with peptides designed to mimic the GSK3b/b-catenin-binding region of MUC1, we have demonstrated that this interaction promotes invasion, and localizes primarily to the leading edges of invading cells.
Peptides in this study were designed to mimic a binding-dense region of the MUC1 cytoplasmic domain. Binding domains for GSK-3b, b-catenin, EGFR tyrosine kinase and c-src kinase all reside within the 24-mer of M1 peptides. If MUC1 is acting as a scaffolding protein to bring together multiple proteins in an invasion-promoting complex, this small, but complex peptide may be providing all the requisite docking sites. It is interesting to note that GSK-3b has previously been identified as interacting with MUC1 in a manner that inhibits MUC1-b-catenin complex formation in vitro. In our invasion system, the presence of a GSK-3b-binding motif does not inhibit the proinvasion signal; in fact, by removing that portion of the peptide (M2), no promotion of invasion can be observed. A binding site for PKCd resides within the GSK-3b-binding site ('TDR', the M3 peptide), the phosphorylation of which promotes binding of b-catenin to MUC1 and invasion in vitro (Ren et al., 2002) . Our invasion-promoting peptides (M1 and M1pY) do not contain the intact PKCd site (but retain functional EGFR and c-src sites), while the M3 peptide does contain the requisite PKCdbinding site, but does not promote invasion. Whether the GSK-3b site is irrelevant or whether the presence of functional EGFR/c-src-binding sites can modulate the effects of GSK3b binding will be the focus of future studies. It is interesting to note, though, that preliminary experiments have shown very strong coimmunoprecipitation of MUC1 with GSK3 in lymph node metastases from invasive breast cancer patients (note that the antibody detects both GSK-3b and a forms; data not shown), indicating that the interaction between these two proteins does not diminish during transformation and invasion. These same patient samples display strong interactions between MUC1 and b-catenin in the lymph node metastases as well (data not shown). Overall, these results suggest that GSK3/MUC1 interactions may share a broader role in tumor development and invasion than that indicated by cell culture data. As these peptides are likely phosphorylated in vivo by the proper kinase, it is probable that the binding and phosphorylation of MUC1 by PKCd compensates for any inhibitory effect of GSK-3b.
Strong in vivo support for the role of Muc1 in tumor development is provided by our observation that tumors form almost twice as slowly in the MMTV-Wnt-1/ Muc1 À/À animals versus the MMTV-Wnt-1/Muc1 +/+ animals. As the histological phenotype or b-catenin expression profile of the tumors is not altered in the absence of Muc1, Muc1 expression may be critical for an intermediate step of tumor progression, such as loss of homotypic cell interaction and a loss of contact inhibition, and future studies will address these possibilities. The ability of Muc1 to affect tumor formation is not limited to the MMTV-Wnt-1 model, but has also been observed in animals overexpressing the polyoma middle T antigen in the mammary gland . In this study, crossing MMTV-mTag transgenics onto the Muc1-null background caused a significant delay in tumor growth and a trend towards decreased pulmonary metastasis. This ability of Muc1 expression to affect the tumor growth in two separate models of mammary gland carcinoma lends strength to the theory that Muc1 functions in a global transformation event, such as promoting cellular invasion into the microenvironment and allowing for tumor expansion. It is important to note that the MMTV-Wnt-1 model of mammary gland carcinoma is primarily one that does not metastasize (Li et al., 2000) . Therefore, its utility as a model to determine the role of Muc1 in promoting distant metastasis is limited. We have begun a study to determine the effects of MUC1 overexpression in this model by creating MMTV-Wnt-1/MMTV-MUC1 bitransgenics. Preliminary data indicate a possible induction of metastatic phenotype, as we have detected pulmonary metastases in 1/3 of the animals generated (data not shown), which may indicate a promotion of invasion in this model. Localization of MUC1 and b-catenin to invading cell membranes suggests a somewhat novel pathway for bcatenin-induced tumorigenesis. Experimental data from the colon cancer system has indicated that b-catenin functions as a proto-oncogene primarily through its ability to translocate to the nucleus and act as a transcriptional cofactor in promoting the transcription of oncogenes such as c-myc and cyclin D1 (He et al., 1998; Shtutman et al., 1999) . While some studies have demonstrated nuclear/cytoplasmic localization of b-catenin in breast cancer patients (Lin et al., 2000) , we and others have been unable to identify significant b-catenin translocation to the nucleus in either our invasive cell lines, spontaneous mouse models or in human breast cancer samples (Rahn et al., 2001 , data not shown). An alternate possibility to nuclear translocation is the recruitment of b-catenin away from the adherens complex and into a separate cytoplasmic complex, where its function as a bridge to the cytoskeleton may be utilized in a non-E-cadherin complex for cytoskeleton rearrangement. b-Catenin is a phosphorylation substrate for the erbB receptors, which can result in the release of b-catenin from adherens junctions (Hazan and Norton, 1998; Piedra et al., 2001) . We have recently observed both the tyrosine phosphorylation of b-catenin by erbB receptors in tumors in the MMTV-Wnt-1 transgenic model, as well as a b-catenin/erbB2 association in human metastatic breast cancer (Schroeder et al., 2002) . Together, these data indicate a biological relevance for the seemingly common event of tyrosine phosphorylation of b-catenin during breast transformation and invasion, to remove it from adherens junctions.
Two of the cell lines used in our invasion assays, MDA-MB-468 and ZR-75-1, have quite high levels of MUC1 protein expression (while MUC1 is almost undetectable in MDA-MB-231 cells) (Walsh et al., 1999) . Additionally, levels of EGFR are also correspondingly high in only the MDA-MB-231 and -468 cell lines (Biscardi et al., 1998) . If indeed phosphorylation of either MUC1 and/or b-catenin by the erbB receptors is required for the induction of this proinvasion cascade, MDA-MB-468 cells are the only cells tested that would respond optimally. Additionally, MDA-MB-468 cells do not express a-catenin (Hazan et al., 1997) , perhaps another factor leading to instability in the E-cadherin/ b-catenin/actin complex at adherens junctions.
We have shown here that MUC1 and b-catenin colocalize with the actin-bundling protein fascin in membrane protrusions of migrating cells, suggesting that this complex plays a role in cell migration. The role of fascin in membrane reorganization has emerged recently, as studies have demonstrated the involvement of fascin in facilitating the tight packing of actin filaments into membrane protrusions such as lamellipodia, microspikes and membrane ruffles (Adams, 1997; Yamashiro et al., 1998) . Interestingly, b-catenin has been shown to interact with fascin in nontransformed cells as well, primarily in nonadherens complexes at the leading edges of migratory epithelial cells (Tao et al., 1996) . Together, these data point to an additional function for b-catenin in the transformation and invasion of breast epithelium, one in which its ability to coordinate organization of the cytoskeleton is the key.
We suggest that the association between MUC1 and b-catenin promotes an alternate localization of bcatenin, away from adherens junctions to sites of membrane protrusions. There, the ability of b-catenin to interact with cytoskeleton-modulating proteins promotes their redistribution and promotes cellular invasion. Therefore, when MUC1 complexes with b-catenin, it promotes the novel interaction between b-catenin and invading cell margins, possibly by simply disrupting the cell adhesion normally found at the adherens junctions. This complex formation may not only promote the transition from hyperplasia to neoplasia in nonmetastatic disease, but also induce the dynamic changes necessary for metastatic invasion.
Experimental procedures
Animals MMTV-Wnt-1 transgenic animals (Tsukamoto et al., 1988) were purchased from Jackson Laboratories and maintained on a Muc1-wild-type or Muc1-null background, or crossed with MMTV-MUC1 full-length transgenics (all on the FVB strain). Note that human MUC1 and mouse Muc1 are delineated in this manner. For the tumor onset study, virgin female animals were palpated weekly while under 1.5% isofluorane anesthesia and sacrificed when the tumor size was between 1.0 and 1.5 cm in diameter.
Immunoprecipitation and immunoblotting
Protein lysates were prepared as described previously (Schroeder et al., 2001 ) and protein concentrations were determined by BCA (Pierce biochemical company). Lysates were either separated by SDS-PAGE and transferred to PVDF membrane directly (Immobilon) or first immunoprecipitated and then separated by SDS-PAGE. Antibodies used for immunoblotting and immunoprecipitation were obtained from the following sources: anti-Muc1 (Schroeder et al., 2001) ] and antib-catenin (H-102, immunoprecipitation and C-18, immunoblotting, both from Santa Cruz Biochemical).
Human tissues and cell lines
Samples of discard tissue from patients with diagnosed infiltrating ductal breast adenocarcinoma undergoing mastectomy or lumpectomy were dissected by Mayo Clinic Hospital pathologists and homogenized directly in lysis buffer (Schroeder et al., 2001) . Homogenized protein lysates were aliquoted and stored at À801C and BCA assays (Pierce) were performed to determine the protein concentration. For immunofluoresence, tissues were fixed in methacarn and paraffin embedded. Note that pathologists dissected tissues for fixation to include both normal breast and normal lymph nodes at the margins of the tumors for comparative staining, while dissecting away all normal tissue for tissue homogenization. MDA-MB-231, MDA-MB-468 and ZR-75-1 human breast cancer cell lines were purchased from ATCC and maintained in DMEM with 5% fetal calf serum (FCS).
Invasion assay
Transwell inserts (Corning) (8 mm pore size) were inverted and coated with 90 ml of Type I collagen (rat tail, BD Scientific) gel mixture (2.2% sodium bicarbonate, 10 Â M199 media), and allowed to solidify for 30 min. Wells were then inverted into DMEM with 20% FCS and allowed to rehydrate. Peptides were incubated with BioPORTER reagent (Gene Therapy Systems Inc., San Diego, CA, USA) for 5 min, vortexed, and added to cells in serum-free media. Cells were then added to the top of the Transwell and incubated for 2.5-5 h. Media were removed and gels were fixed with 4% paraformaldehyde for 30 min and transferred to PBS, pH 7.4. Collagen gels were then either stained with bizbenzamide for 40 min and all cells that invaded into a gel were enumerated or used in immunofluorescence assays.
Peptides
Biotinylated peptides were synthesized at Mayo Clinic Rochester Protein Core Facility. Peptides were resuspended in PBS, pH 7.4, with protease inhibitors (Complete, Roche Biochemicals) and phosphatase inhibitors (2 mm sodium orthovanadate, 1 mm sodium flouride and 1 mm ammonium molybdate) prior to addition to the cells.
Immunofluoresence
Tissue sections were analysed as described previously (Schroeder et al., 2001) , with the addition of an antigen retrieval step (BD Retrievagen A, Pharmingen). Antibodies used for tissue immunofluorescence are as follows: anti-MUC1 (B27.29-FITC, 1 : 500, a gift from Biomira), anti-b-catenin (H-102, 1 : 500, Santa Cruz Biochemical and A11010-Alexa546, 1 : 500, Molecular Probes). For immunofluorescence on collagen gels, gels were permeablized with 0.5% Triton X-100 in 10 mm Pipes (pH 6.8), 50 mm NaCl, 300 mm sucrose and 3 mm MgCl 2 for 5 min at room temperature. Gels were then blocked with 3% BSA (Sigma), 0.05% Tween-20, in a 1 : 1 solution of PBS and Enhancing Wash Buffer (Innovex). Primary antibodies were incubated overnight at 41C, and gels were washed for 6 h in 1 : 1 PBS: Enhancing Wash Buffer. Secondary antibodies were incubated overnight at 41C, and washed again for 6 h at room temperature. Gels were then mounted, coverslipped and analysed using a Zeiss laser scanning confocal microscope. Antibodies used were as follows: antibiotin (streptavidin-Alexa594, 1 : 500, Molecular Probes), anti-Muc1 (Schroeder et al., 2001) , antivinculin (V9131, 1 : 400, Sigma Chemical Company) antib-catenin (H-102, 1 : 100, Santa Cruz Biochemical), antifascin (FCN01, 1 : 50, Neomarkers) and phalloidinAlexa546 (1 : 100, Molecular Probes). Secondary antibodies were either Alexa 488 or 546 from Molecular Probes.
